These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

746 related items for PubMed ID: 23942873

  • 1. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
    Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, Gertler SZ, Song X, Graham N, Dent S.
    Breast Cancer Res Treat; 2013 Aug; 141(1):111-7. PubMed ID: 23942873
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 4. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
    Swenson KK, Nissen MJ, Henly SJ, Maybon L, Pupkes J, Zwicky K, Tsai ML, Shapiro AC.
    Oncol Nurs Forum; 2013 Nov 10; 40(6):549-57. PubMed ID: 24161633
    [Abstract] [Full Text] [Related]

  • 5. The influence of endocrine treatments for breast cancer on health-related quality of life.
    Buijs C, de Vries EG, Mourits MJ, Willemse PH.
    Cancer Treat Rev; 2008 Nov 10; 34(7):640-55. PubMed ID: 18514425
    [Abstract] [Full Text] [Related]

  • 6. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    Breast International Group (BIG) 1-98 Collaborative GroupSenology Center of Eastern Switzerland, Kantonsspital, St. Gallen, and the Swiss Group for Clinical Cancer Research, Switzerland., Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.
    N Engl J Med; 2005 Dec 29; 353(26):2747-57. PubMed ID: 16382061
    [Abstract] [Full Text] [Related]

  • 7. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
    Le Ray I, Dell'Aniello S, Bonnetain F, Azoulay L, Suissa S.
    Breast Cancer Res Treat; 2012 Sep 29; 135(2):603-9. PubMed ID: 22903687
    [Abstract] [Full Text] [Related]

  • 8. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ.
    Oncology; 2005 Sep 29; 69(1):1-9. PubMed ID: 16088229
    [Abstract] [Full Text] [Related]

  • 9. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2014 Jul 29; 146(1):109-16. PubMed ID: 24816806
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
    Mandalà M, Moro C, Ferretti G, Calabro MG, Nolè F, Rocca A, Munzone E, Castro A, Curigliano G.
    Anticancer Res; 2001 Jul 29; 21(1B):585-8. PubMed ID: 11299809
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS, El-Hajj II, Makarem JA, Otrock ZK.
    Anticancer Drugs; 2006 Sep 29; 17(8):999-1002. PubMed ID: 16940812
    [Abstract] [Full Text] [Related]

  • 18. Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.
    Dorfman CS, Arthur SS, Kimmick GG, Westbrook KW, Marcom PK, Corbett C, Edmond SN, Shelby RA.
    Menopause; 2019 Aug 29; 26(8):823-832. PubMed ID: 30994574
    [Abstract] [Full Text] [Related]

  • 19. Endocrine therapy for early breast cancer.
    Hussain SA, Williams S, Stevens A, Rea DW.
    Expert Rev Anticancer Ther; 2004 Oct 29; 4(5):877-88. PubMed ID: 15485321
    [Abstract] [Full Text] [Related]

  • 20. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
    Nabholtz JM.
    Oncology; 2006 Oct 29; 70(1):1-12. PubMed ID: 16439860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.